A lack of mergers has allowed them to stay focused on strategy, Their alliances have been a success.
It is our top pick. I like the lack of patent expirations...They have a portfolio of new products.
It is our top pick. I like the lack of patent expirations... They have a portfolio of new products.
We view this as a critical event in the Pfizer story and a potential positive catalyst for the stock.
We view this announcement, following Pfizer's 26% dividend increase in December 2005, as another sign that Pfizer is addressing shareholder concerns and as another step in the right direction for the company.
Trading at 12 times 2005 earnings, shares are reflecting a seemingly bearish view of Pfizer's growth prospects, in our opinion. With these low expectations built into the shares, we are encouraged that Pfizer's $4 billion cost restructuring will stabilize near-term earnings.
I think Hank's credibility has been hurt but I think he has admitted that. I think he needs to be upfront about how they are handling all the variables facing the business.
